SheMed is a London-based digital health company focused on clinically supervised weight-loss programs designed specifically for women. The company has raised $50 million in total funding through its Series A round, reaching a $1 billion valuation. The funding supports SheMed’s integrated care model combining at-home blood testing, clinician oversight, subscription-based treatment kits, and a mobile health app. Its capital strategy reflects strong investor confidence in personalized, AI-enabled disease self-management and women’s health platforms.